An advocacy group has asked the National Institutes of Health to investigate whether several patents held by Aegerion Pharmaceuticals failed to disclose federal funding for grants that were used to develop a pricey cholesterol treatment.

In its request, the advocacy group cited a federal database showing six patents were awarded to the University of Pennsylvania, where an academic researcher used NIH grants to develop a drug called Juxtapid, which was later licensed to Aegerion Pharmaceuticals. The school has received more than $68 million in grants for research led by Dr. Daniel Rader, who chairs the genetics department at the Perelman School of Medicine, and at least $293,000 pertained to his work on Juxtapid, according to Knowledge Ecology International, the advocacy group.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy